Abstract 32P
Background
International guidelines recommend a combination of NK1, 5-HT3 receptor antagonists, and dexamethasone (DEX) as standard antiemetic therapy for patients treated with a doxorubicin and cyclophosphamide (AC) regimen. However, DEX has been associated with several side effects, including diabetes, osteoporosis, and immunosuppression. Additionally, pneumocystis pneumonia, a rare but fatal condition, has been reported, predominantly in patients undergoing the dose-dense AC (ddAC) regimen.
Methods
We recruited 30 patients with Stage I-III breast cancer who received the ddAC regimen. Patients were administered prophylactic olanzapine (OLZ) 5 mg/day on days 1 to 4 in addition to the standard three-drug combination antiemetic regimen, with DEX omitted on days 2 and 3. Nausea/vomiting and drowsiness were evaluated using a 4-point Likert scale questionnaire previously employed in the J-FORCE study, which assessed the efficacy of OLZ 5 mg in high-emetic-risk regimens. The primary endpoint was complete response (CR) rate in the delayed phase (24-120 hours post chemotherapy administration) of the first cycle. Secondary endpoints included the total control (TC) rate of nausea and vomiting, complete control (CC) rate, degree of daytime sleepiness, and quality of life as assessed by EORTC QLQ-C30 Ver.3.
Results
Among the participants, 22 patients (73%) received ddAC as neoadjuvant chemotherapy and 8 (27%) as adjuvant chemotherapy. Median age at the start of treatment was 56 years. CR rates were 73% and 63% in the acute and delayed periods, respectively. TC and CC rates in the acute period were 60% and 73%, whereas those in the delayed period were 36.6% and 63%, respectively. In both periods, 40% of patients experienced moderate or severe sleepiness. Mean scale scores for nausea on the EORTC QLQ-C30 remained within the Minimally Important Difference score level throughout the 4th cycles of treatment.
Conclusions
This prospective pilot study suggests that the addition of OLZ 5mg allows the omission of steroids without a worsening of CINV in patients with ddAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract